Floatz logo

Glycosylated Recombinant Human Interleukin-7

Stage III Renal Pelvis Cancer AJCC v8

National Cancer Institute (NCI)Phase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Stage III Renal Pelvis Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3B
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Epirubicin
Alliance for Clinical Trials in Oncology
Phase 3B
Cyclophosphamide
Alliance for Clinical Trials in Oncology
Phase 3B
Ipilimumab
M.D. Anderson Cancer Center
Phase 2B

View all 11 →

Same molecule, other indications

Glycosylated Recombinant Human Interleukin-7 is also rated in:

hypogonadismDormant
CCC
Indicative ·
52 / 100
View asset →
metastatic prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →